Potential public health impact of a Neisseria meningitidis A, B, C, W, and Y pentavalent vaccine in the United States

Figures & data

Figure 1. Meningococcal infection model.

IMD = invasive meningococcal disease; MenACWY = quadrivalent vaccine for serogroups A, C, W, and Y.

Table 1. IMD incidence by serogroup and age.*

	Serogroup
Age, y	B	C	W	Y
0–5, 6–12 mo	0.623	0.077	0.027	0.043
1, 2–4	0.090	0.047	0.013	0.010
5–10	0.023	0.010	0	0
11–15	0.023	0.007	0	0
16–23	0.113	0.017	0.010	0.010
24–44	0.027	0.030	0.010	0.010
45–64	0.023	0.027	0.013	0.013
≥65	0.030	0.023	0.020	0.037

*IMD incidence per 100,000 person-years. Calculations were derived from the Centers for Disease Control and Prevention enhanced meningococcal disease surveillance reports from 2015–2017.

IMD = invasive meningococcal disease.

Table 2. Vaccine efficacy assumptions.*

Vaccine Inputs	MenB Vaccine	MenACWY Vaccine
Protection against invasive disease	85% (2 dose completion) [19] 30% (1 dose completion) [19,28]	95% [20,21,23]
Protection against carriage	0% [27,28]	36.2% [26]
Duration of protection against disease	5 y [33]	5 y [34–36]
Duration of protection against carriage	N/A	5 y [34–36]
Annual decrease in disease protection	10%^† [13,29–32]	10%^† [34–36]
Annual decrease in carriage protection	N/A	10%^† [34–36]

*Vaccine characteristics of MenABCWY were assumed to be similar to MenB and MenACWY vaccines.

^†The 10% annual waning rate for the MenABCWY vaccine was a conservative assumption based on cited sources.

MenABCWY = meningococcal serogroups A, B, C, W, and Y; MenACWY = meningococcal serogroups A, C, W, and Y; MenB = meningococcal serogroup B; N/A = not applicable.

Figure 2. Estimated number of IMD cases averted over 10 years in the United States under various vaccine administration strategies.*

*Due to differences in rounding, the sum of MenB and MenACWY disease averted may differ slightly from the total number of IMD cases averted.^†Base case analysis.^‡Sensitivity analysis. Vaccination administration schedules are shown separated by dark gray lines; base case and sensitivity analyses for each vaccination schedule are shown separated by a light gray line. IMD = invasive meningococcal disease; MenACWY = meningococcal serogroups A, C, W, and Y; MenABCWY = meningococcal serogroups A, B, C, W, and Y; MenB = meningococcal serogroup B.

Vesikari T, Ostergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc. 2016;5(2):152–160.

 PubMed Web of Science ®Google Scholar

McMillan M, Walters L, Sullivan T, et al. Impact of meningococcal B (4CMenB) vaccine on pharyngeal Neisseria meningitidis carriage density and persistence in adolescents. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa610. [Epub ahead of print].

 Google Scholar

Bermal N, Huang LM, Dubey A, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin. 2011;7(2):239–247.

 PubMed Web of Science ®Google Scholar

Baxter R, Baine Y, Kolhe D, et al. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J. 2015;34(11):1236–1243.

 PubMed Web of Science ®Google Scholar

Nimenrix (meningococcal group A, C, W-135 and Y conjugate vaccine). Summary of Product Characteristics. Pfizer Ltd: Sandwich, UK; 2019.

 Google Scholar

Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–327.

 PubMed Web of Science ®Google Scholar

Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–2131.

 PubMed Web of Science ®Google Scholar

Vesikari T, Ostergaard L, Beeeslaar J, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019;37(12):1710–1719.

 PubMed Web of Science ®Google Scholar

Breton MC, Huang L, Snedecor SJ, et al. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada. Can J Public Health. 2020;111(2):182–192.

 PubMed Web of Science ®Google Scholar

Data availability statement

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study.